Biomarker Research Services Help Discover, Develop, Test, and Validate Biomarkers


Biomarker Research Services

Biomarkers are increasingly being used in all therapeutic areas of medicine to help in the prognosis and characterization of the disease. Biomarkers play an important role in understanding the development of chronic human diseases and the identification of subgroups that are at increased risk for disease. Moreover, over the years, they have been widely used in all fields of medicine to diagnose a particular disease. The increasing focus on biomarkers is expected to increase the demand for biomarker research services in the development and validation of new biomarkers.

Various contract research organizations provide biomarker research services for the discovery, development, testing, and validation of biomarkers. These organizations provide different types of biomarker research services to their customers, such as commercialization, biomarker validation, research assay optimization, verification, qualification, and biomarker discovery. Biotechnology companies, pharmaceutical organizations, and research institutes partner or collaborate with service providers for commercialization, validation, and development of biomarkers, as well as companion diagnostic.

For instance, in 2019, BioIVT collaborated with the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium to develop and support research to qualify promising biomarkers for improving clinical practice, predicting therapeutic response, or diagnosing diseases. BioIVT provides services in various countries worldwide, such as the U.S., the U.K., Singapore, Italy, etc. Biomarker research services are specifically provided for the development and validation of new biomarkers.

Companion diagnostic is a test or medical device used to determine and validate drug applicability in a specific individual, as well as risk, safety, and benefit from that drug. Qualified biomarkers have the ability to deliver valuable information that can help during drug development. Furthermore, in 2017, with an investment of US$ 215 million, the National Institutes of Health launched Precision Medicine Initiative to accelerate biomedical research and offer new tools to select therapies that can be used in a more individualized approach with patients.